University of Texas's MD Anderson: Researchers Identify Surface Protein as a New Osteosarcoma Therapeutic Target for Antibody-Drug Conjugates
April 13, 2021
April 13, 2021
HOUSTON, Texas, April 13 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 12, 2021:
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins thr . . .
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins thr . . .